Bayhill Therapeutics Announces The Successful Clearance Of An IND For BHT-3034 For The Treatment Of Myasthenia Gravis

Links shared publicly online about this topic.

  • 467
    total visits

Bayhill Therapeutics Announces The Successful Clearance Of An IND For BHT-3034 For The Treatment Of Myasthenia Gravis

medicalnewstoday.com —

Bayhill Therapeutics Inc, a clinical-stage biopharmaceutical company utilizing its proprietary BHT-DNA™ platform to develop novel and targeted autoimmune and immune-mediated disease treatme

View full resource at medicalnewstoday.com

Tags: Disease and Condition, disease

  • Share

Most Recently Shared on March 3, 2011 at 10:05 am By:

mnt_drugapprov MNT Drug Approvals

Bayhill Therapeutics Announces The Successful Clearance Of An IND For BHT-3034 For The Treatment Of Myasthenia Gravis http://mnt.to/3RNk

1 year ago...

Reply

Retweet

Favorite

Also Shared By:

MNT Neurology News MNT Neurology News

MNT Bones/Orthopedic MNT Bones/Orthopedic

Advertisement